ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1641

Long-term Cardiovascular Disease and Mortality Following Kawasaki Disease in Childhood: A Systematic Review

Francis Lao1, Cal Robinson2, Megan Schlorff1, Jocelyne Ewusie3, Karen Beattie1 and Michelle Batthish1, 1McMaster University, Hamilton, ON, Canada, 2The Hospital for Sick Children, Hamilton, ON, Canada, 3St Joseph's Healthcare, Hamilton, ON, Canada

Meeting: ACR Convergence 2021

Keywords: Cardiovascular, Pediatric rheumatology, Vasculitis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 9, 2021

Title: Pediatric Rheumatology – Clinical Poster III: Miscellaneous Rheumatic Disease (1614–1644)

Session Type: Poster Session D

Session Time: 8:30AM-10:30AM

Background/Purpose: Kawasaki Disease (KD) is a common vasculitis of childhood, with an annual North American incidence of 20-26 per 100,000 children (< 5 years of age). Coronary artery aneurysms (CAAs) develop in 25% of untreated KD patients. There are no precise estimates of the long-term cardiovascular (CV) events following childhood KD diagnosis. We aimed to determine the incidence of long-term CV events and mortality following KD diagnosis.

Methods: A systematic search of MEDLINE, EMBASE, CINAHL, Cochrane, and Web of Science databases was performed through 2019. Initial screening was performed by 2 independent reviewers. Inclusion criteria included English-only publications, patients 0-18 years at KD diagnosis, minimum follow-up >1 year, and ≥10 patients included in original clinical data. CV events (myocardial infarction (MI), heart failure (HF), cardiac arrest) and mortality were extracted and pooled for analysis. The Newcastle-Ottawa Scale assessed study quality focusing on participant selection, comparability, and measurement of outcome or ascertainment of exposure. This review was submitted to PROSPERO on November 23, 2019 and registered on April 28, 2020.

Results: Of 4225 articles identified, 170 were included in the review (Figure 1). The distribution of study designs was: 123 retrospective cohort studies, 54 prospective cohort studies, 2 case series, 13 cross-sectional studies, 1 case control study, and 4 interventional studies. A total of 167 articles had quality assessment scores ≥6 out of a maximum score of 9. The number of studies reporting coronary artery stenosis, coronary artery thrombosis, coronary artery occlusion, CV events and death are displayed in Table 1.

Among 86,812 KD patients across 110 studies, there were 1519 events of MI, HF, or cardiac arrest (1.8%). A subgroup analysis was performed, stratifying studies by CAA status of participants: no/few CAAs (≤ 10% of study participants), some CAAs (11-99% of study participants), all CAAs (100% of study participants). This was performed to determine the effect of CAAs on incidence of CV events and mortality. Composite CV events occurred in 457 of 29,393 (1.55%) in no/few CAAs study participants, 502 of 15,049 (3.34%) some CAAs study participants, and 446 of 3970 (11.23%) all CAAs study participants (Table 2).

Across 99 studies, 1137 of 106,497 KD (1.07%) patients died. When stratified based on the proportion of patients in the study with CAAs: death occurred in 75 of 33,845 (0.22%) in no/few CAAs study participants, 157 of 14299 (1.10%) in some CAAs participants, and 114 of 3948 (2.89%) in all CAAs study participants (Table 2).

Conclusion: This study comprises the largest review of long-term cardiovascular outcomes of KD. Children with KD are at risk of developing long-term CV events, including MI, heart failure and cardiac arrest. Those with coronary artery aneurysms are especially at higher risk. Further studies are needed to better define these risks.

Figure 1: PRISMA flow diagram of study selection

Table 1: Number of studies reporting at least one case of coronary artery stenosis/thrombosis/occlusion, CV events and death.

Table 2: Incidence of cardiovascular events (myocardial infarction, heart failure, and cardiac arrest) and all-cause mortality.


Disclosures: F. Lao, None; C. Robinson, None; M. Schlorff, None; J. Ewusie, None; K. Beattie, None; M. Batthish, Abbvie, 5, Novartis, 6, Mylan, 1, Sobi, 1.

To cite this abstract in AMA style:

Lao F, Robinson C, Schlorff M, Ewusie J, Beattie K, Batthish M. Long-term Cardiovascular Disease and Mortality Following Kawasaki Disease in Childhood: A Systematic Review [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/long-term-cardiovascular-disease-and-mortality-following-kawasaki-disease-in-childhood-a-systematic-review/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/long-term-cardiovascular-disease-and-mortality-following-kawasaki-disease-in-childhood-a-systematic-review/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology